Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

NCT02896582 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Obinutuzumab
DRUG: Dexamethasone
DRUG: Aracytine
DRUG: Cisplatinum
DRUG: Etoposide
DRUG: Melphalan
DRUG: Carmustine

Sponsor

The Lymphoma Academic Research Organisation